Peregrine's VTA Inhibits Growth of Breast Cancer Tumor Metastases by up to 58 Percent

Peregrine's VTA & Docetaxel Combination Therapy Inhibits Human Breast Cancer Growth by 93% in Pre-Clinical Studies

Peregrine Pharmaceuticals Presents Summary of Clinical Experience of Tumor Necrosis Therapy

Peregrine Pharmaceuticals Announces Grant of Broad Claims in Europe for its Vascular Targeting Agent Technology

Peregrine Pharmaceuticals Announces Publication of Data Related to its Tumor Necrosis Therapy Technology Platform

Peregrine Pharmaceuticals Announces Patent Grant for Vascular Targeting Agents That Target Vascular Endothelial Growth Factor

Peregrine Pharmaceuticals Announces Patent Grant For Vasopermeation Enhancement Technology

Peregrine's Vascular Targeting Agent Technology Reviewed In 'Clinical Cancer Research'

Peregrine's Cotara(R) Phase I Hepatic Cancer Study Published In 'Cancer Therapy'

Peregrine Pharmaceuticals Announces Patent Grant For Anti-Angiogenic Treatments Using VEGF Inhibition